Does the media prefer VYGR or ABUS?

In the previous week, Voyager Therapeutics had 2 more articles in the media than Arbutus Biopharma. MarketBeat recorded 4 mentions for Voyager Therapeutics and 2 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.93 beat Voyager Therapeutics' score of 0.63 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arbutus Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ETON or VYGR?

In the previous week, Voyager Therapeutics had 2 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 4 mentions for Voyager Therapeutics and 2 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 0.94 beat Voyager Therapeutics' score of 0.63 indicating that Eton Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Voyager Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KURA or VYGR?

In the previous week, Voyager Therapeutics had 2 more articles in the media than Kura Oncology. MarketBeat recorded 4 mentions for Voyager Therapeutics and 2 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 1.25 beat Voyager Therapeutics' score of 0.63 indicating that Kura Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Voyager Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VYGR or SANA?

In the previous week, Voyager Therapeutics had 2 more articles in the media than Sana Biotechnology. MarketBeat recorded 4 mentions for Voyager Therapeutics and 2 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 1.31 beat Voyager Therapeutics' score of 0.63 indicating that Sana Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sana Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Voyager Therapeutics (VYGR) Competitors

$3.50 -0.08 (-2.23%)

Closing price 04:00 PM Eastern

Extended Trading

$3.59 +0.09 (+2.69%)

As of 07:51 PM Eastern

Compare

VYGR vs. ABUS, ETON, KURA, ORIC, and SANA

Should you buy Voyager Therapeutics stock or one of its competitors? MarketBeat compares Voyager Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Voyager Therapeutics include Arbutus Biopharma (ABUS), Eton Pharmaceuticals (ETON), Kura Oncology (KURA), Oric Pharmaceuticals (ORIC), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry.

How does Voyager Therapeutics compare to Arbutus Biopharma?

Voyager Therapeutics (NASDAQ:VYGR) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Voyager Therapeutics has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

Arbutus Biopharma has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	5.24	-$119.72M	-$1.97	N/A
Arbutus Biopharma	$14.08M	67.34	-$33.50M	$0.83	5.78

In the previous week, Voyager Therapeutics had 2 more articles in the media than Arbutus Biopharma. MarketBeat recorded 4 mentions for Voyager Therapeutics and 2 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.93 beat Voyager Therapeutics' score of 0.63 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arbutus Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Voyager Therapeutics currently has a consensus price target of $16.50, indicating a potential upside of 371.43%. Arbutus Biopharma has a consensus price target of $5.00, indicating a potential upside of 4.17%. Given Voyager Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Voyager Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 12.7% of Voyager Therapeutics shares are owned by insiders. Comparatively, 19.9% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Arbutus Biopharma has a net margin of 83.95% compared to Voyager Therapeutics' net margin of -319.61%. Arbutus Biopharma's return on equity of 129.32% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-319.61%	-55.97%	-43.12%
Arbutus Biopharma	83.95%	129.32%	112.24%

Summary

Arbutus Biopharma beats Voyager Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Voyager Therapeutics compare to Eton Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

Eton Pharmaceuticals presently has a consensus price target of $41.00, suggesting a potential upside of 13.26%. Voyager Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 371.43%. Given Voyager Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Voyager Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Voyager Therapeutics had 2 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 4 mentions for Voyager Therapeutics and 2 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 0.94 beat Voyager Therapeutics' score of 0.63 indicating that Eton Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Voyager Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by company insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Eton Pharmaceuticals has a net margin of -1.70% compared to Voyager Therapeutics' net margin of -319.61%. Eton Pharmaceuticals' return on equity of -5.68% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%
Voyager Therapeutics	-319.61%	-55.97%	-43.12%

Eton Pharmaceuticals has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market.

Eton Pharmaceuticals has higher revenue and earnings than Voyager Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	12.40	-$4.60M	-$0.07	N/A
Voyager Therapeutics	$40.37M	5.24	-$119.72M	-$1.97	N/A

Summary

Eton Pharmaceuticals beats Voyager Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Voyager Therapeutics compare to Kura Oncology?

Kura Oncology (NASDAQ:KURA) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

Kura Oncology currently has a consensus target price of $25.46, suggesting a potential upside of 132.10%. Voyager Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 371.43%. Given Voyager Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Voyager Therapeutics is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Kura Oncology has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market.

48.0% of Voyager Therapeutics shares are held by institutional investors. 7.6% of Kura Oncology shares are held by insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Voyager Therapeutics had 2 more articles in the media than Kura Oncology. MarketBeat recorded 4 mentions for Voyager Therapeutics and 2 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 1.25 beat Voyager Therapeutics' score of 0.63 indicating that Kura Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Voyager Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Voyager Therapeutics has a net margin of -319.61% compared to Kura Oncology's net margin of -411.19%. Voyager Therapeutics' return on equity of -55.97% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-411.19%	-141.95%	-43.28%
Voyager Therapeutics	-319.61%	-55.97%	-43.12%

Voyager Therapeutics has lower revenue, but higher earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	14.43	-$278.67M	-$3.35	N/A
Voyager Therapeutics	$40.37M	5.24	-$119.72M	-$1.97	N/A

Summary

Voyager Therapeutics beats Kura Oncology on 13 of the 17 factors compared between the two stocks.

How does Voyager Therapeutics compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

Oric Pharmaceuticals has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market.

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by insiders. Comparatively, 12.7% of Voyager Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Oric Pharmaceuticals has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. Oric Pharmaceuticals' return on equity of -35.33% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Voyager Therapeutics	-319.61%	-55.97%	-43.12%

Voyager Therapeutics has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Voyager Therapeutics	$40.37M	5.24	-$119.72M	-$1.97	N/A

Oric Pharmaceuticals presently has a consensus target price of $18.92, indicating a potential upside of 74.67%. Voyager Therapeutics has a consensus target price of $16.50, indicating a potential upside of 371.43%. Given Voyager Therapeutics' higher possible upside, analysts clearly believe Voyager Therapeutics is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Voyager Therapeutics had 3 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 4 mentions for Voyager Therapeutics and 1 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 1.89 beat Voyager Therapeutics' score of 0.63 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Oric Pharmaceuticals	Very Positive
Voyager Therapeutics	Positive

Summary

Oric Pharmaceuticals and Voyager Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Voyager Therapeutics compare to Sana Biotechnology?

Voyager Therapeutics (NASDAQ:VYGR) and Sana Biotechnology (NASDAQ:SANA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

In the previous week, Voyager Therapeutics had 2 more articles in the media than Sana Biotechnology. MarketBeat recorded 4 mentions for Voyager Therapeutics and 2 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 1.31 beat Voyager Therapeutics' score of 0.63 indicating that Sana Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sana Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Voyager Therapeutics currently has a consensus price target of $16.50, suggesting a potential upside of 371.43%. Sana Biotechnology has a consensus price target of $9.50, suggesting a potential upside of 172.21%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Voyager Therapeutics is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Voyager Therapeutics has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market.

Voyager Therapeutics has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	5.24	-$119.72M	-$1.97	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by company insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Sana Biotechnology has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. Voyager Therapeutics' return on equity of -55.97% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-319.61%	-55.97%	-43.12%
Sana Biotechnology	N/A	-108.01%	-40.68%

Summary

Voyager Therapeutics and Sana Biotechnology tied by winning 8 of the 16 factors compared between the two stocks.

Get Voyager Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VYGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VYGR vs. The Competition

Export

Metric	Voyager Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$216.31M	$3.66B	$6.87B	$12.45B
Dividend Yield	N/A	2.20%	2.67%	6.16%
P/E Ratio	-1.78	20.90	27.51	24.87
Price / Sales	5.24	341.80	540.69	102.84
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	0.99	8.75	11.01	6.54
Net Income	-$119.72M	$23.81M	$3.57B	$336.70M
7 Day Performance	-5.41%	3.64%	2.56%	3.31%
1 Month Performance	-9.56%	1.64%	0.89%	1.68%
1 Year Performance	12.54%	69.47%	36.84%	31.96%

Voyager Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VYGR Voyager Therapeutics	3.6851 of 5 stars	$3.50 -2.2%	$16.50 +371.4%	+20.9%	$216.31M	$40.37M	N/A	100	News Coverage
ABUS Arbutus Biopharma	0.9163 of 5 stars	$4.52 -0.7%	$5.00 +10.6%	+49.5%	$898.80M	$14.08M	5.45	90	High Trading Volume
ETON Eton Pharmaceuticals	2.7027 of 5 stars	$32.72 +0.7%	$41.00 +25.3%	+162.2%	$889.70M	$79.95M	N/A	20
KURA Kura Oncology	2.9991 of 5 stars	$10.36 +4.3%	$25.46 +145.8%	+93.5%	$881.53M	$67.48M	N/A	130	Positive News
ORIC Oric Pharmaceuticals	2.7287 of 5 stars	$8.93 +5.2%	$18.92 +111.8%	-1.6%	$878.86M	N/A	N/A	80	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VYGR) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Voyager Therapeutics (VYGR) Competitors

VYGR vs. ABUS, ETON, KURA, ORIC, and SANA

How does Voyager Therapeutics compare to Arbutus Biopharma?

Summary

How does Voyager Therapeutics compare to Eton Pharmaceuticals?

Summary

How does Voyager Therapeutics compare to Kura Oncology?

Summary

How does Voyager Therapeutics compare to Oric Pharmaceuticals?

Summary

How does Voyager Therapeutics compare to Sana Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYGR vs. The Competition

Voyager Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Voyager Therapeutics (VYGR) Competitors

VYGR vs. ABUS, ETON, KURA, ORIC, and SANA

How does Voyager Therapeutics compare to Arbutus Biopharma?

Which has more risk & volatility, VYGR or ABUS?

Which has higher earnings and valuation, VYGR or ABUS?

Does the media prefer VYGR or ABUS?

Do analysts rate VYGR or ABUS?

Do insiders & institutionals have more ownership in VYGR or ABUS?

Is VYGR or ABUS more profitable?

Summary

How does Voyager Therapeutics compare to Eton Pharmaceuticals?

Do analysts rate ETON or VYGR?

Does the media refer more to ETON or VYGR?

Do insiders and institutionals have more ownership in ETON or VYGR?

Is ETON or VYGR more profitable?

Which has more volatility and risk, ETON or VYGR?

Which has higher earnings and valuation, ETON or VYGR?

Summary

How does Voyager Therapeutics compare to Kura Oncology?

Do analysts prefer KURA or VYGR?

Which has more risk and volatility, KURA or VYGR?

Do insiders & institutionals have more ownership in KURA or VYGR?

Does the media refer more to KURA or VYGR?

Is KURA or VYGR more profitable?

Which has preferable earnings & valuation, KURA or VYGR?

Summary

How does Voyager Therapeutics compare to Oric Pharmaceuticals?

Which has more risk & volatility, ORIC or VYGR?

Do institutionals & insiders have more ownership in ORIC or VYGR?

Is ORIC or VYGR more profitable?

Which has better earnings & valuation, ORIC or VYGR?

Do analysts prefer ORIC or VYGR?

Does the media favor ORIC or VYGR?

Summary

How does Voyager Therapeutics compare to Sana Biotechnology?

Does the media prefer VYGR or SANA?

Do analysts recommend VYGR or SANA?

Which has more risk & volatility, VYGR or SANA?

Which has preferable valuation and earnings, VYGR or SANA?

Do institutionals and insiders have more ownership in VYGR or SANA?

Is VYGR or SANA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYGR vs. The Competition

Voyager Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools